SEPN
Septerna, Inc. Common StockSEPN
SEPN
About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
–
Funds holding %
of 6,812 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
50%
upside
Avg. target
$44
72%
upside
High target
$50
97%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Josh Schimmer 37% 1-year accuracy 22 / 59 met price target | 97%upside $50 | Overweight Initiated | 19 Nov 2024 |
Wells Fargo Derek Archila 50% 1-year accuracy 18 / 36 met price target | 70%upside $43 | Overweight Initiated | 19 Nov 2024 |
JP Morgan Eric Joseph 52% 1-year accuracy 15 / 29 met price target | 50%upside $38 | Overweight Initiated | 19 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.
Neutral
GlobeNewsWire
1 month ago
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases
Positive
Benzinga
1 month ago
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
Neutral
GlobeNewsWire
1 month ago
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna.
Positive
Seeking Alpha
2 months ago
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, Septerna, and WeRide. Several small issuers also listed this past week, including Synergy CHC, High Roller Technologies, SAG Holdings, and Li Bang. Two IPOs are tentatively scheduled to list in the week ahead, although some small issuers may join the calendar throughout the week - Peak Resources and Jinxin Technology.
Positive
Reuters
2 months ago
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut
Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.
Neutral
GlobeNewsWire
2 months ago
Septerna Prices Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of 16,000,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Septerna has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Septerna, and the common stock is expected to begin trading on the Nasdaq Global Market on October 25, 2024, under the ticker symbol “SEPN.”
Positive
Reuters
2 months ago
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO
Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.
Positive
Reuters
2 months ago
Biotech Septerna aims to raise up to $186 million in US IPO
Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.
Positive
Seeking Alpha
2 months ago
Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline
Septerna, Inc. aims to raise $100 million in an IPO to advance its clinical-stage biopharma treatments for endocrine diseases, with SEP-786 in Phase 1 trials. The hypoparathyroidism treatment market is expected to grow at a robust CAGR of 6.9% from 2024 to 2032, driven by increased diagnoses and treatments. The firm is backed by top-tier life science investors and is well-capitalized but faces typical biopharma risks, including future financing needs and potential trial failures.
Charts implemented using Lightweight Charts™